The IL-4/IL-13 antagonist, IgG1, and an anti-IgE monoclonal antibody (Omalizumab®) have been administered as dried powder inhaler preparations for asthma, chronic obstructive pulmonary disease (COPD), or other related lung diseases [75]. This evidence concerns the gene IL4 and chronic obstructive pulmonary disease.